- Home
- NBH vs CRMD Comparison
NBH vs CRMD Comparison
Compare NBH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- CRMD
- Stock Information
- Founded
- NBH 2002
- CRMD 2006
- Country
- NBH United States
- CRMD United States
- Employees
- NBH N/A
- CRMD N/A
- Industry
- NBH Finance/Investors Services
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- CRMD Health Care
- Exchange
- NBH Nasdaq
- CRMD Nasdaq
- Market Cap
- NBH 292.3M
- CRMD 925.6M
- IPO Year
- NBH N/A
- CRMD 2010
- Fundamental
- Price
- NBH $10.48
- CRMD $11.12
- Analyst Decision
- NBH
- CRMD Strong Buy
- Analyst Count
- NBH 0
- CRMD 8
- Target Price
- NBH N/A
- CRMD $17.57
- AVG Volume (30 Days)
- NBH 85.9K
- CRMD 4.6M
- Earning Date
- NBH 01-01-0001
- CRMD 10-29-2025
- Dividend Yield
- NBH 4.34%
- CRMD N/A
- EPS Growth
- NBH N/A
- CRMD N/A
- EPS
- NBH 0.12
- CRMD 0.79
- Revenue
- NBH N/A
- CRMD $121,484,498.00
- Revenue This Year
- NBH N/A
- CRMD $404.81
- Revenue Next Year
- NBH N/A
- CRMD $56.11
- P/E Ratio
- NBH $87.04
- CRMD $14.00
- Revenue Growth
- NBH N/A
- CRMD 14970.29
- 52 Week Low
- NBH $8.75
- CRMD $5.60
- 52 Week High
- NBH $11.01
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- NBH 81.89
- CRMD 34.64
- Support Level
- NBH $9.77
- CRMD $12.73
- Resistance Level
- NBH $9.95
- CRMD $13.83
- Average True Range (ATR)
- NBH 0.09
- CRMD 0.81
- MACD
- NBH 0.05
- CRMD -0.30
- Stochastic Oscillator
- NBH 97.93
- CRMD 0.90
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.